What drug class does Enasidenib belong to?

Enasidenib is an oral small molecule drug that belongs to the IDH2 inhibitor category of targeted therapy drugs. Its unique mechanism of action makes it an important drug for the treatment of acute myeloid leukemia (AML). IDH2 (isocitrate dehydrogenase 2) is an important metabolic enzyme that plays a key role in cellular energy generation and metabolism. IDH2 mutation is one of the common genetic mutations in AML. Mutations can lead to abnormal cell metabolism, thereby promoting the occurrence and development of cancer.

The main function of ensidipine is to inhibit the activity of IDH2 mutant enzyme, promote the differentiation of leukemia cells by restoring normal cell metabolism, and return them to normal blood cell functions. This mechanism is completely different from traditional chemotherapy drugs. Traditional chemotherapy drugs often treat cancer by inhibiting the growth of rapidly dividing cells, but this can also damage normal cells. Ensidipine targets IDH2 mutations more precisely and mainly acts on cancer cells. It does not affect other cells in the body as extensively as chemotherapy, thereby reducing damage to normal cells.

Ensidipine is a targeted drug, which is a major advancement in the field of cancer treatment in recent years. The advantage of targeted therapy drugs lies in their precise effect on specific molecular targets, which can effectively improve the therapeutic effect while reducing side effects. Compared with traditional chemotherapy, targeted drugs can inhibit tumor growth more precisely, and are especially suitable for patients who have developed drug resistance or cannot be controlled by other treatments.

As an IDH2 inhibitor, ensidipine has not only made significant progress in the treatment of acute myeloid leukemia, but it has also opened up a new path for personalized treatment. Clinically, ensidipine has been used to treat AML patients with IDH2 gene mutations, especially those who do not respond to or are resistant to traditional treatments. By targeting specific mutations, ensidipine effectively improves treatment response rates and reduces the risk of relapse.

Reference materials:https://www.idhifa.com/